PDS Biotechnology price target lowered to $3 from $5 at B. Riley

Group 1 - B. Riley has lowered the price target on PDS Biotechnology (PDSB) to $3 from $5 while maintaining a Buy rating on the shares [1] - The shares are considered attractively valued with near-zero enterprise value (EV) that does not reflect the impact of the recent strategic pivot on enrollment size, efficacy endpoint durations, and an enriched p16+ve population with limited competing trials [1]